Dendritic cell therapy in cancer treatment; the state-of-the-art

DC vaccines in detail

DC vaccines in detail



Dendritic Cell Immunotherapy is a new alternative for cancer treatment. DC is obtained from the patient and modulated in other to boost the immune system toward tumour elimination. Several approaches have been on the evaluation for long-term anti-tumor immune responses by DCs. Additionally, Dendritic Cell Therapy can be primary and can also be combined with other cancer therapies, such as chemotherapy.


Cancer immunotherapy is a new and exciting alternative for cancer treatment. The therapy uses the body’s own immune system to fight against cancer cells, and can be used as a stand-alone treatment or in conjunction with other treatments such as chemotherapy. Learn more about how this procedure works and its advantages over traditional methods of cancer treatment today!


The human immune system is a complex and intricate network of cells, tissues, organs, and other bodily functions. If it wasn’t for the immune system we would all be susceptible to diseases like cancer. The development of immunotherapy has led to an increased number of people living longer after diagnosis because there are now treatment options that can fight the disease without chemotherapy or radiation therapy.


In this post, we show through a scientific article the fundamentals of immunotherapy for cancer treatment. Immunotherapy is a new and exciting field of oncology that has been met with great hope in regards to clinical efficacy.



Dendritic cells are the most important and critical part in the stimulation of anti-tumor immunity. DCs are responsible for stimulating T cell responses by presenting peptides from tumor cells to them, thereby activating these cytotoxic lymphocytes. Therefore, it is imperative that DCs be able to deliver immunogenic tumor peptides without being destroyed or hijacked by tumors themselves.
The future of cancer immunotherapy is likely to be built upon combination of two arms. One arm will focus on inhibiting tumor-induced immunosuppression, while the second arm will aim to activate antitumor immunity.

Article Reference link: click here

Scientific article publishing date : 19/3/2020

Immucura identifier : BSC21_013EN